Medynex has launched AZAFLUNEX, a new hybrid nasal spray combining azelastine and fluticasone propionate, to treat moderate seasonal and perennial allergic rhinitis in adults and children aged 12 and older.
The introduction of AZAFLUNEX, as reported by VIDAL, provides a therapeutic alternative for patients who do not achieve sufficient symptom relief through monotherapy—the use of a single active ingredient—such as an antihistamine or an intranasal corticosteroid alone. By combining an H1 receptor antagonist and a corticosteroid, the spray targets both the immediate allergic response and the underlying nasal inflammation.
- Mechanism of Action: It pairs azelastine, which blocks histamine receptors and stabilizes mast cells, with fluticasone, a potent corticosteroid that reduces tissue swelling and inflammation.
- Treatment Protocol: The recommended dosage is one spray in each nostril twice daily; consistent use is required to reach maximum clinical efficacy.
- Device Maintenance: Users must prime the pump with six actuations before the first use and one actuation if the device remains unused for more than seven days.
AZAFLUNEX is officially classified as a hybrid of the existing treatment DYMISTA. According to the product registration, it is indicated specifically for moderate to severe allergic rhinitis where previous single-agent treatments have failed to control symptoms. The medication is categorized under “Liste I,” meaning it requires a prescription.
The product has been granted a 30% reimbursement rate by the French health insurance system, with a public retail price of 7,75 euros per bottle. Each bottle contains 120 measured doses. The product is also approved for use in public healthcare facilities, ensuring broader access for patients treated within the hospital system.
While the hybrid formulation is designed for efficacy, it is not a first-line treatment; it is reserved for cases where monotherapy is insufficient. The suspension must be discarded six months after its initial activation.
| Feature | Specification |
|---|---|
| Active Ingredients | Azelastine (137 µg) / Fluticasone (50 µg) |
| Target Age | 12 years and older |
| Posology | 1 spray per nostril, twice daily |
| Device Capacity | 120 actuations |
| Regulatory Category | Liste I (Prescription required) |
To ensure the efficacy of the suspension, Medynex provides specific handling instructions for the patient. The bottle must be agitated gently for five seconds by turning it over repeatedly before every application. Patients are advised to clear their nasal passages by blowing their nose prior to administration to ensure the spray reaches the target mucosa effectively.
Administration should occur with the head tilted slightly downward. Following each use, the spray nozzle must be cleaned, and the protective cap replaced to prevent contamination. These steps are essential to maintain the stability of the suspension throughout the six-month usage window.
- VIDAL, “AZAFLUNEX : hybride de DYMISTA pour traiter la rhinite allergique,” November 2026.